147116-64-1

Basic information

• Product Name: ezlopitant
• Synonyms: ezlopitant
• CAS NO: 147116-64-1
• Molecular Formula: C31H38N2O
• Molecular Weight: 454.64622
• Mol File: 147116-64-1.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 570.3°Cat760mmHg
• Flash Point: 298.7°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 5.08E-13mmHg at 25°C
• Refractive Index: 1.614
• CAS DataBase Reference: ezlopitant(CAS DataBase Reference)
• NIST Chemistry Reference: ezlopitant(147116-64-1)
• EPA Substance Registry System: ezlopitant(147116-64-1)

Safety Data

• Hazardous Substances Data: 147116-64-1(Hazardous Substances Data)

Usage

Uses

Treatment of emesis, pain, and inflammation (substance P [NK-1] receptor antagonist).

InChI:InChI=1/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1

Relevant articles and documents

Pharmaceutical composition and method of modulating cholinergic function in a mammal

A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed.

Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles

The present invention relates to methods of treating various CNS and other disorders by adminstering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formula wherein Q,

NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SYMPTOMS OF IRRITABLE BOWEL SYNDROME

The present invention relates to a method of treating or preventing symptoms of irritable bowel syndrome in a mammal, including a human, using a compound that is an NK-1 receptor antagonist, in particular a substance P receptor antagonist.